As President of Global Health at Novartis, Lutz Hegemann, MD, PhD, is responsible for integrating global health and environmental, social and governance (ESG) matters into the core of the Novartis business.
In this role, Dr. Hegemann leads two teams: the ESG Management Office, which integrates ESG activities across the company; and the Global Health organization, which focuses on transforming health in low- and middle-income countries, with flagship programs targeting malaria, leprosy, sickle cell disease and Chagas disease.
In his ad interim role as Chief Strategy & Growth Officer, he leads a newly created Strategy & Growth function for Novartis, spanning corporate strategy, research and development portfolio strategy and business development.
Before taking on his present role, Lutz was Group Head of Corporate Affairs and Global Health. He has held roles of increasing responsibility since joining Novartis in 2005 in the Consumer Health Division. He began his career as a public health physician and scientist.
Dr. Hegemann is a Fellow of the Royal Society of Tropical Medicine and Hygiene. He serves on the board of directors of the Novartis Foundation, the Swiss Alliance against Neglected Tropical Diseases, and the Tanzania Training Centre for International Health.
On the board of directors at PATH, Dr. Hegemann is a member of the Governance, Impact and Responsibility Committee.
Appointed to the board: June 2021